A natural analog of glutamate
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

L-Quisqualic Acid

Item No. 20211

Technical Information
Formal Name
αS-amino-3,5-dioxo-1,2,4-oxadiazolidine-2-propanoic acid
CAS Number
52809-07-1
Molecular Formula
C5H7N3O5
Formula Weight
Purity
≥95%
Formulation
A solid
SMILES
O=C1NC(N(C[C@@H](C(O)=O)N)O1)=O
InChi Code
InChI=1S/C5H7N3O5/c6-2(3(9)10)1-8-4(11)7-5(12)13-8/h2H,1,6H2,(H,9,10)(H,7,11,12)/t2-/m0/s1
InChi Key
ASNFTDCKZKHJSW-REOHCLBHSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    L-Quisqualic acid is a natural analog of glutamate that acts as an agonist at AMPA-selective and metabotropic glutamate receptors (EC50s = 170, 10, 40, and 29 nM at GluR-A, mGluR1, mGluR3, and mGluR5, respectively), as well as the ionotropic kainate receptor (GRIK4; Ki = 6.43 nM).1,2,3,4,5,6 L-Quisqualic acid is used to study receptor dynamics and as an excitotoxin to selectively destroy neurons in the brain or spinal cord.7,8

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Schoepp, D.D., Jane, D.E., and Monn, J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38(10), 1431-1476 (1999).

    2. Bräuner-Osborne, H., Egebjerg, J., Nielsen, E.O., et alLigands for glutamate receptors: Design and therapeutic prospects. J. Med. Chem. 43(14), 2609-2645 (2000).

    3. Bertrand, H.-O., Besis, A.-S., Pin, J.-P., et alCommon and selective molecular determinants involved in metabotopic glutamate receptor agonist activity. J. Med. Chem. 45(15), 3171-3183 (2002).

    4. Kamboj, R.K., Schoepp, D.D., Nutt, S., et alMolecular cloning, expression, and pharmacological characterization of humEAA1, a human kainate receptor subunit. J.Neurochem. 62(1), 1-9 (1994).

    5. Mutel, V., Ellis, G.J., Adam, G., et alCharacterization of [3H]quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J. Neurochem. 75(6), 2590-2601 (2000).

    6. Uchino, S., Sakimura, K., Nagahari, K., et alMutations in a putative agonist binding region of the AMPA-selective glutamate receptor channel. FEBS Lett. 308(3), 253-257 (1992).

    7. Lee, J.-W., Furmanski, O., Castellanos, D.A., et alProlonged nociceptive responses to hind paw formalin injection in rats with a spinal cord injury. Neurosci. Lett. 439(2), 212-215 (2008).

    8. Muir, J.L., Page, K.J., Sirinathsinghji, D.J.S., et alExcitotoxic lesions of basal forebrain cholinergic neurons: effects on learning, memory and attention. Behav. Brain Res. 57(2), 123-131 (1993).